Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Brief Summary: This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin. The primary hypothesis of this study is that after 52 weeks, the change from baseline in hemoglobin A1c (A1C) in participants treated with the addition of ertugliflozin 15 mg once daily is non-inferior compared with that in participants treated with the addition of glimepiride.


Options:
A: Arm Label: BI 1356 (5 mg); Type: EXPERIMENTAL; Interventions: Drug: Linagliptin + pioglitazone (30 mg) | Arm Label: Placebo matching BI 1356 5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + pioglitazone (30 mg) | Intervention Type: DRUG; Name: placebo + pioglitazone (30 mg); Assigned to Arm(s): Placebo matching BI 1356 5 mg | Intervention Type: DRUG; Name: Linagliptin + pioglitazone (30 mg); Assigned to Arm(s): BI 1356 (5 mg)
B: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
C: Arm Label: Ertugliflozin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ertugliflozin 5 mg, Drug: Placebo to Ertugliflozin, Drug: Placebo to Glimepiride, Drug: Metformin, Drug: Sitagliptin | Arm Label: Ertugliflozin 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Ertugliflozin 5 mg, Drug: Ertugliflozin 10 mg, Drug: Placebo to Glimepiride, Drug: Metformin, Drug: Sitagliptin | Arm Label: Glimepiride up to 8 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimerpiride, Drug: Placebo to Ertugliflozin, Drug: Metformin, Drug: Sitagliptin | Intervention Type: DRUG; Name: Ertugliflozin 5 mg; Assigned to Arm(s): Ertugliflozin 15 mg, Ertugliflozin 5 mg | Intervention Type: DRUG; Name: Ertugliflozin 10 mg; Assigned to Arm(s): Ertugliflozin 15 mg | Intervention Type: DRUG; Name: Glimerpiride; Assigned to Arm(s): Glimepiride up to 8 mg | Intervention Type: DRUG; Name: Placebo to Ertugliflozin; Assigned to Arm(s): Ertugliflozin 5 mg, Glimepiride up to 8 mg | Intervention Type: DRUG; Name: Placebo to Glimepiride; Assigned to Arm(s): Ertugliflozin 15 mg, Ertugliflozin 5 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Ertugliflozin 15 mg, Ertugliflozin 5 mg, Glimepiride up to 8 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Ertugliflozin 15 mg, Ertugliflozin 5 mg, Glimepiride up to 8 mg
D: Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300 mg, Drug: Metformin, Drug: Sulphonylurea | Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin 100 mg, Drug: Metformin, Drug: Sulphonylurea | Intervention Type: DRUG; Name: Sitagliptin 100 mg; Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Canagliflozin 300 mg; Assigned to Arm(s): Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 300 mg, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Sulphonylurea; Assigned to Arm(s): Canagliflozin 300 mg, Sitagliptin 100 mg

Answer: C